OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
OMass Therapeutics has raised $12.5M in total funding. The most recent round was Series B. The last funding was announced in May 2023.
OMass Therapeutics's investors include Oxford Science Enterprises, Google Ventures, Northpond Ventures, University of Oxford, Sanofi Ventures.
OMass Therapeutics is headquartered in Oxford, United Kingdom.
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
OMass Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OMass Therapeutics — Funding & Investors." VCBacked, May 15, 2023, https://www.vcbacked.co/company/omass-therapeutics. Accessed September 13, 2026.
VCBacked. (2023). OMass Therapeutics — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/omass-therapeutics
{{cite web |title=OMass Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/omass-therapeutics |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated